Tatva Chintan Pharma Chem Ltd
NSE: TATVA BSE: 543321Pharma
Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals[1]
₹1,255
52W: ₹750 — ₹1610
PE 75.1 · Book ₹324 · +287% vs bookMarket Cap₹2,936 Cr
Stock P/E75.1Price to Earnings
ROCE6.85%Return on Capital
ROE5.28%Return on Equity
Div. Yield0.08%Face Value ₹10
Strengths
- +Company is expected to give good quarter
- +Company's working capital requirements have reduced from 124 days to 80.2 days
Weaknesses
- −Stock is trading at 3.80 times its book value
- −The company has delivered a poor sales growth of 11.2% over past five years.
- −Company has a low return on equity of 3.31% over last 3 years.
- −Debtor days have increased from 82.4 to 106 days.
- −Promoter holding has decreased over last 3 years: -7.15%
Shareholding Pattern
Promoters72.02%
FIIs3.81%
DIIs2.99%
Public21.16%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% | 72.02% |
| FIIs | 3.37% | 3.33%▼0.0 | 3.36%▲0.0 | 3.3%▼0.1 | 3.26%▼0.0 | 3.4%▲0.1 | 4.17%▲0.8 | 3.81%▼0.4 |
| DIIs | 10.64% | 6.83%▼3.8 | 6.34%▼0.5 | 5.46%▼0.9 | 5.11%▼0.3 | 3.87%▼1.2 | 3.32%▼0.6 | 2.99%▼0.3 |
| Public | 13.97% | 17.81%▲3.8 | 18.27%▲0.5 | 19.21%▲0.9 | 19.6%▲0.4 | 20.72%▲1.1 | 20.49%▼0.2 | 21.16%▲0.7 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 86.07 | 93.93 | 93.81 | 80.96 | 84 | 107.65 | 109.18 | 115.86 | 138.59 | 132.67 |
| Expenses | 73.75 | 79.73 | 86.12 | 76.37 | 78.35 | 99.75 | 94.12 | 94.74 | 111.97 | 106.13 |
| Operating Profit | 12.32 | 14.2 | 7.69 | 4.59 | 5.65 | 7.9 | 15.06 | 21.12 | 26.62 | 26.54 |
| OPM % | 14.31% | 15.12% | 8.2% | 5.67% | 6.73% | 7.34% | 13.79% | 18.23% | 19.21% | 20% |
| Net Profit | 4.65 | 8.25 | 1.51 | -1.11 | -1.17 | 1.1 | 5.13 | 8.94 | 15.98 | 9.02 |
| EPS ₹ | 1.99 | 3.53 | 0.65 | -0.47 | -0.5 | 0.47 | 2.19 | 3.82 | 6.83 | 3.86 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹496Cr, up 35.5% YoY. OPM at 18%.
Debt Position
Borrowings at ₹120Cr. Debt-to-equity ratio: 0.16x. Healthy balance sheet.
Capex Cycle
CWIP at ₹23Cr (4% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 2.99% (-8.08pp change). FIIs: 3.81% (+0.62pp change). Promoters hold 72.02%.
Margin & Efficiency
ROCE improving from 0% (Mar 2018) to 7% (Mar 2026). Working capital days: 80.
Valuation
PE 75.1x with 6.85% ROCE. Price is 287% above book value of ₹324. Dividend yield: 0.08%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 24h - Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Financial Year ended 31 March 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 1d - Earnings call recording held on 16 May 2026 is now available on the company website.
- Announcement under Regulation 30 (LODR)-Investor Presentation 1d - Investor Presentation for the quarter and financial year ended 31 March 2026.
- Announcement under Regulation 30 (LODR)-Change in Management 1d - FY26 audited results approved; final dividend Rs 2/share, cost auditor and internal auditor appointed.
- Corporate Action-Board approves Dividend 1d - FY26 audited results approved; board recommends Rs 2 final dividend and appoints cost and internal auditors.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse